2.Company name:Microbio Co., Ltd.

3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office

4.Reciprocal shareholding ratios:NA

5.Cause of occurrence:

The Company has been informed by the patent agency that the new drug, MS-20,has

been granted a Korea patent titled “COMBINED CANCER THERAPY WITH IMMUNE

CHECKPOINT MODULATORS AND FERMENTATION PRODUCTS BY SYMBIOTIC

MICROBIOTA”under patent number 10-2646979.

6.Countermeasures:None.

7.Any other matters that need to be specified(the information disclosure also meets the

requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement

Rules, which brings forth a significant impact on shareholders rights or the price of the

securities on public companies.):

(1)The new drug MS-20 has obtained patents from the U.S., the Republic of China,

Japan, the People’s Republic of China, the Hong Kong Special Administrative

Region, Europe, Korea, Indonesia, India, Canada, Singapore, Malaysia,

Brazil, and United Arab Emirates.

(2)This patent presents a combination therapy with Chemo young (MS-20) and

anti-PD1 antibody to enhance the anti-cancer efficacy of immune checkpoint

modulators.